[Press release – not published yet] Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 trial

News release: Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Commentaries: J&J’s one-shot COVID vaccine offers hope for faster protection – Nature AND Johnson & Johnson Executive Says Vaccine Works Where It Counts: Preventing Deaths – NPR AND Novavax’s COVID Vaccine Shows High Efficacy In Trials; J&J One-Dose Shot Less So – As Europe Feuds With AstraZeneca – Health Policy Watch AND Covid vaccine: Single-dose Johnson & Johnson jab is 66% effective – BBC AND Johnson & Johnson’s COVID-19 Vaccine Results Are Better Than They May Sound – TIME AND Expert reaction to Johnson & Johnson announcing that the single-shot Janssen COVID-19 vaccine candidate met primary endpoints in the interim analysis of its phase 3 ENSEMBLE Trial – Science Media Centre AND Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released – NIH News Releases AND J&J one-dose Covid vaccine is 66% effective, a weapon but not a knockout punch – STAT